| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Advanced glycosylation end product-specific receptor;Receptor for advanced glycosylation end products;AGER;RAGE; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human KIF3A Microtubule-based anterograde translocator for membranous organelles. Plus end-ed microtubule sliding activity in vitro. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-KIF3A antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone ACEO-11; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IP (as provided in the source record). Boster Bio Anti-KIF3A Monoclonal Antibody catalog # M03439. Tested in WB, IP applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: KIF3A (Advanced glycosylation end product-specific receptor).
- Antibody format: Monoclonal; clone ACEO-11; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
KIF3A (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF- alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides. . Reported cellular localization context: Isoform 1: Cell membrane; Single-pass type I membrane protein. Tissue expression notes (as provided): Endothelial cells.
Research relevance and current trends
- Research context keywords from the source record include: Adapters,Cytoskeleton,Cytoskeleton/ECM,Motor Proteins,Neuroscience,Neurotransmitter,Protein Trafficking,Signal Transduction,Signaling Pathways,Stem Cells,Surface Molecules,Transporters,Vesicle Transport.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunoprecipitation (IP): enrich target complexes for downstream immunoblot or interaction analyses.
Workflow ideas (metafield): Validate KIF3A antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect KIF3A expression by Western blot in cell or tissue lysates, Enrich KIF3A by immunoprecipitation from lysates for downstream analysis
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 150 kDa; calculated MW: 42803 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 150 kDa
- Cellular localization (provided): Isoform 1: Cell membrane; Single-pass type I membrane protein.
- Tissue details (provided): Endothelial cells.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
